SCHEMBL3564553

SCHEMBL3564553

O=C=Nc1ccc(C(F)(F)F)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.47
CYP3A4 P08684 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TRPA1 O75762 1/20 0.34
CYP2C9 P11712 1/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
SLC22A11 Q9NSA0 1/20 0.34
DAO P14920 2/20 0.33
KCNH2 Q12809 2/20 0.33
PIK3CA P42336 2/20 0.33
PI4KB Q9UBF8 2/20 0.33
HDAC4 P56524 1/20 0.33
MAP4K4 O95819 1/20 0.33
MINK1 Q8N4C8 1/20 0.33
SLC40A1 Q9NP59 1/20 0.32
USP30 Q70CQ3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14661056 0.86 TRPV4 (0.42) TRPV4CYP3A4TSHRKCNH2PIK3CA
SCHEMBL30406321 0.81 TRPV4 (0.47) TRPV4CYP3A4TDP1CYP2C9SLC22A6
SCHEMBL16014037 0.81 TRPV4 (0.47) TRPV4CYP3A4TDP1CYP2C9SLC22A6
SCHEMBL1246261 0.75 TRPV4 (0.52) TRPV4CYP2C9SLC22A6SLC22A8SLC22A12
SCHEMBL16023759 0.75 TRPV4 (0.52) TRPV4CYP3A4CYP2C9SLC22A6SLC22A8
SCHEMBL19879960 0.75 TRPV4 (0.52) TRPV4CYP3A4CYP2C9SLC22A6SLC22A8
SCHEMBL28631538 0.75 CYP3A4 (0.42) CYP3A4TSHRMAPK1TDP1TRPA1
SCHEMBL1191458 0.73 LOXL2 (0.43) CYP3A4TSHRMAPK1TDP1TRPA1
SCHEMBL30520078 0.72 CYP3A4 (0.43) CYP3A4TSHRMAPK1TDP1TRPA1
SCHEMBL1783888 0.72 CYP3A4 (0.43) CYP3A4TSHRMAPK1TDP1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145927-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use BRISTOL-MYERS SQUIBB COMPANY (US) 2024-11-19 US disclosed
US-20210355113-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB COMPANY 2021-11-18 US disclosed
WO-2020023356-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB COMPANY (US) 2020-01-30 WO disclosed
US-8710049-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 US disclosed
US-20130184262-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
WO-2013012829-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
US-7666873-B2 N-phenyl-(2R,5S)dimethylpiperazine derivative ASTELLAS PHARMA INC. (JP) 2010-02-23 US disclosed
US-20080214543-A1 N-Phenyl-(2R,5S)Dimethylpiperazine Derivative ASTELLAS PHARMA INC. (JP) 2008-09-04 US disclosed
US-7297698-B2 N-phenyl-(2R,5S) dimethylpiperazine derivative ASTELLAS PHARMA INC. (JP) 2007-11-20 US disclosed
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1557411-A1 N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative BPHL, QDPR, SRD5A2 TRPV4 557/4885CYP3A4 409/4885TSHR 3307/4885
US-20130184262-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R TRPV4 123/4885CYP3A4 1357/4885TSHR 245/4885
US-12145927-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use IDO1, IDO2, INMT TRPV4 3106/4885CYP3A4 506/4885TSHR 3165/4885
US-20080214543-A1 N-Phenyl-(2R,5S)Dimethylpiperazine Derivative BPHL, AR, SRD5A2 TRPV4 914/4885CYP3A4 497/4885TSHR 3434/4885
US-20210355113-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE IDO1, IDO2, INMT TRPV4 3106/4885CYP3A4 506/4885TSHR 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.